CLSPN and osteosarcoma: This result was further confirmed by using siRNA to knock down Claspin expression in U2OS osteosarcoma cells (Supplementary Figure S9F), which elsewhere we have shown are sensitive to CCT244747 treatment but can be adapted to become CHK1i resistant [24].